Home » Newsletters » BioWorld

BioWorld

Sep. 2, 1993

View Archived Issues

PERSEPTIVE TO ACQUIRE MASS SPECTROMETRY COMPANY

CLOT-BUSTER STUDY RESULTS PUBLISHED

IMMUNOGEN TESTS ONCOLYSIN S

IVAX COMPLETES JOHNSON PRODUCTS MERGER

STOCK PURCHASE BRINGS VIRATEK $14M

VESTAR ENTERS TAXOL MARKET

FDA POSTPONES REVIEW OF RESPIVIR

FDA APPROVES HYGEIA PHARMACEUTICALS TRIALS

CYANOTECH GETS FUNDING FOR PRODUCTION FACILITY

SOUTH KOREA OKS BTG'S BIOLON By Brenda Sandburg

APS COMPLETES PHASE III TRIALS

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...